SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics ($MLTX) is trending due to a significant stock drop following analyst downgrades and concerns over clinical trial data for their drug, sonelokimab, with RBC Capital citing uncompetitive effect size. The community is debating whether the sell-off is an overreaction, with some seeing a buying opportunity due to the company's cash reserves and pipeline, while others express concern over biotech volatility and potential risks. Discussions also include speculation about potential buyouts and the impact of institutional ownership on the stock's price movement.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the crypto community focuses on its potential to represent and revolutionize cannabis culture. Discussions highlight Weedcoin's mission to foster a positive community and bridge culture with cryptocurrency. Some traders are speculating about potential catalysts from cannabis-related news and broader discussions around the future of the cannabis industry.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending, with the community actively engaging in the 'What's UpDog?' joke and highlighting its presence on the $SOL.X network. Community members emphasize that it's been active for over a year and is listed on Jupiter Strict List while also congratulating other trending tickers on being UpDog. The coin is also associated with meme culture, with many users sharing related content and humor.

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Dogwood Therapeutics Inc.

Dogwood Therapeutics is trending as traders discuss its low float and potential for a significant price surge, drawing comparisons to similar past runners. The community is closely watching for news related to upcoming Phase 2 data on Halneuron and potential partnerships for IMC-1, with some speculating on a potential squeeze due to limited shares available for borrowing.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is trending as investors anticipate data from its nomlabofusp clinical development program for Friedreich's Ataxia, expected sometime this month. Community members are weighing the potential for positive results and a subsequent rise in stock price, while also considering the risk of negative outcomes given the high short interest and upcoming conference call to discuss updates. Some traders are noting unusual options activity, suggesting significant potential movement in either direction post-announcement.

JFB Construction Holdings is a commercial and residential real estate construction and development company, which engages in delivering services to commercial and residential markets. It operates through the following segments: Commercial Construction, Residential Construction, and Real Estate Development. The Commercial Construction segment includes all activities related to the construction of commercial properties. The Residential Construction segment focuses on the construction of residential properties including single-family homes and multi-family units. The Real Estate Development segment refers to the acquisition, development, and sale of real estate properties. The company was founded by Joseph F. Basille III on April 9, 2024 and is headquartered in Lantana, FL.

JFB Construction Holdings - Ordinary Shares - Class A

JFB is trending due to a recently announced private placement of approximately $44 million, sparking significant after-hours trading activity. The community is actively discussing the stock's potential for a short squeeze, noting its small float and high short interest. Some traders are also pointing to potential dilution from warrants associated with the private placement.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following a Morgan Stanley downgrade, citing concerns about Alzheimer's trial risks, prescription trends, pricing pressures, and competition; however, the community is actively debating whether this downgrade is a strategic move to accumulate shares cheaply before positive news emerges, with some suggesting analysts are manipulating the stock for their benefit. While some express concern about the increased competition and potential margin squeeze, others emphasize the company's history of innovation and potential for long-term growth, particularly with its upcoming oral Wegovy and expansion into key markets like India.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

GLD is trending as gold prices reach new all-time highs, fueled by expectations of Fed rate cuts and safe-haven demand amid geopolitical tensions. The community is discussing whether this rally has more room to run, with some pointing to a potential currency collapse while others worry about overbought conditions and an impending correction. Broader market context includes de-dollarization and strong central bank buying, influencing the conversation around gold's role as a store of value.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USAR is trending due to news around potential government funding and strategic initiatives in the rare earth sector, including discussions of reallocating funds from the CHIPS Act. The community is actively discussing the implications of these developments, particularly in relation to domestic supply chains and competition with China. Some are also noting insider selling, as well as upcoming milestones for the company's magnet production and mine development.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals (ENTA) is trending due to mixed Phase 2b study results for its RSV treatment, zelicapavir, causing investor debate and a stock sell-off. While the primary endpoint was missed, secondary endpoints were met, fueling discussions about the drug's potential and Phase 3 progression, particularly regarding FDA priorities. Community talking points include potential short squeezes given the high short interest and oversold RSI.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now?

As precision oncology advances, Tempus and Illumina lead the way with innovation. Which stock shows stronger growth momentum now?

Here's Why Illumina (ILMN) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Tempus AI Enhances Cancer Research Tools With FDA-Cleared xR IVD

TEM secures FDA clearance for its xR IVD device, advancing RNA-based cancer research and precision medicine tools.

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025 

GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.

ILMN Stock to Gain From the Launch of Illumina Protein Prep Assay

The Illumina Protein Prep rollout boosts multiomics, strengthens disease insights and supports ILMN stock momentum.

CRISPR Therapeutics (CRSP) Down 5.3% Since Last Earnings Report: Can It Rebound?

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term

TMO Receives FDA Approval for Oncomine Dx Target Test

Thermo Fisher secures FDA approval for its Oncomine Dx Target Test to identify NSCLC patients eligible for HERNEXEOS treatment.

KMDA vs. ILMN: Which Stock Is the Better Value Option?

Illumina (ILMN) Reliance on International Sales: What Investors Need to Know

Evaluate Illumina's (ILMN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Illumina Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

ILMN
Illumina Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ILMN News

ILMN Illumina Inc